SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CAVAZZINI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.270
AS - Asia 8.397
EU - Europa 4.399
SA - Sud America 1.136
Continente sconosciuto - Info sul continente non disponibili 336
AF - Africa 174
OC - Oceania 20
AN - Antartide 1
Totale 29.733
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.860
SG - Singapore 3.037
CN - Cina 2.053
IT - Italia 969
VN - Vietnam 888
DE - Germania 864
BR - Brasile 861
HK - Hong Kong 650
UA - Ucraina 560
TR - Turchia 523
BD - Bangladesh 463
GB - Regno Unito 445
FI - Finlandia 335
FR - Francia 272
SE - Svezia 245
RU - Federazione Russa 226
JP - Giappone 200
CA - Canada 193
IN - India 159
MX - Messico 138
PL - Polonia 121
ID - Indonesia 98
AR - Argentina 95
ZA - Sudafrica 72
NL - Olanda 64
IQ - Iraq 62
EC - Ecuador 49
BE - Belgio 45
ES - Italia 45
CZ - Repubblica Ceca 43
CO - Colombia 33
LT - Lituania 32
PK - Pakistan 32
AT - Austria 29
SA - Arabia Saudita 29
MY - Malesia 27
VE - Venezuela 27
CL - Cile 26
UZ - Uzbekistan 26
MA - Marocco 21
PH - Filippine 20
AE - Emirati Arabi Uniti 16
NP - Nepal 16
TN - Tunisia 16
AU - Australia 15
KE - Kenya 15
EG - Egitto 14
IL - Israele 14
RO - Romania 14
DZ - Algeria 12
CH - Svizzera 11
ET - Etiopia 11
PE - Perù 11
UY - Uruguay 11
BO - Bolivia 10
CR - Costa Rica 10
IE - Irlanda 10
JM - Giamaica 10
JO - Giordania 10
PY - Paraguay 10
DK - Danimarca 9
KR - Corea 9
DO - Repubblica Dominicana 8
HN - Honduras 8
TH - Thailandia 8
TT - Trinidad e Tobago 8
BG - Bulgaria 7
PS - Palestinian Territory 7
PT - Portogallo 7
AL - Albania 6
HR - Croazia 6
OM - Oman 6
EU - Europa 5
GR - Grecia 5
IR - Iran 5
KZ - Kazakistan 5
LV - Lettonia 5
QA - Qatar 5
AZ - Azerbaigian 4
BB - Barbados 4
BH - Bahrain 4
GT - Guatemala 4
HU - Ungheria 4
LB - Libano 4
NI - Nicaragua 4
PR - Porto Rico 4
RS - Serbia 4
SV - El Salvador 4
BY - Bielorussia 3
KG - Kirghizistan 3
LY - Libia 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
PA - Panama 3
SR - Suriname 3
BA - Bosnia-Erzegovina 2
CI - Costa d'Avorio 2
CW - ???statistics.table.value.countryCode.CW??? 2
DM - Dominica 2
EE - Estonia 2
Totale 29.363
Salva come PNG Salva come JPEG
Città #
Singapore 1.985
Ashburn 1.862
Woodbridge 1.239
Fairfield 1.181
San Jose 944
Houston 842
Beijing 796
Chandler 645
Santa Clara 641
Hong Kong 636
Jacksonville 628
Ann Arbor 487
Seattle 458
Wilmington 430
Cambridge 380
New York 369
Dallas 297
Los Angeles 292
Ho Chi Minh City 277
Council Bluffs 246
Izmir 229
Hanoi 201
Nanjing 199
Munich 192
Ferrara 191
Tokyo 183
Princeton 170
Lauterbourg 143
Milan 136
Boardman 131
Helsinki 129
Warsaw 117
San Diego 115
São Paulo 103
Shanghai 102
Addison 90
Turku 86
Mexico City 84
Buffalo 79
Toronto 76
Orem 73
London 70
Chicago 68
Shenyang 68
Jakarta 66
Nanchang 64
Rome 55
Da Nang 54
Phoenix 52
Brooklyn 51
Denver 51
Montreal 49
The Dalles 47
Bremen 45
Chennai 45
Hebei 45
Brussels 43
Stockholm 43
Rio de Janeiro 41
San Francisco 41
Tianjin 40
Johannesburg 38
Haiphong 37
Hefei 37
Atlanta 35
Columbus 35
Frankfurt am Main 35
Falls Church 33
Moscow 33
Redwood City 32
Changsha 31
Jinan 31
Boston 30
Poplar 30
Falkenstein 29
Manchester 29
Jiaxing 28
Guangzhou 26
Baghdad 25
Brno 25
Amsterdam 24
Mountain View 23
Zhengzhou 23
Dong Ket 22
Ankara 21
Dearborn 21
Mumbai 21
Biên Hòa 20
Bologna 20
Des Moines 20
Nuremberg 20
Belo Horizonte 19
Norwalk 19
Naples 18
Newark 18
Quito 18
Tashkent 18
Florence 17
Guayaquil 17
Philadelphia 17
Totale 19.497
Salva come PNG Salva come JPEG
Nome #
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI 316
Diagnostic work-up for clinical and prognostic assessment of acute leukaemia 296
Acute Human Herpesvirus-6A infection of human mesothelial cells modulates HLA molecules 291
Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death 285
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: Clinical and biological correlations 280
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. 275
CYTOGENETIC ABERRATIONS IN THE CD38 POSITIVE FRACTION OF CD38 NEGATIVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: A MARKER OF AGGRESSIVENESS? 274
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 273
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 268
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 268
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy 267
A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma 266
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis 263
Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 261
Soluble urokinase-type Plasminogen Activator Receptor (suPAR) as an independent factor predicting worse prognosis and extra bone marrow involvement in multiple myeloma patients 255
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 255
B-Cell chronic lymphocytic leukemia (B-CLL) with 14q32 translocations: haematological features and clinical outcome. 254
CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 254
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype 253
Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients 249
Chromosome Aberrations by Conventional Karyotyping in Chronic Lymphocytic Leukemia Carrying No Aberration by Fluorescence in Situ Hybridization: Correlation with Prognostic Parameters and Clinical Features 249
Myelofibrosis with Myeloid Metaplasia (MMM)/Idiopathic myelofibrosis/Agnogenic myeloid metaplasia 240
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations 239
Alterations of loci encoding PU.1, BOB1, and OCT2 transcription regulators do not correlate with their suppressed expression in Hodgkin lymphoma. 235
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 235
Secondary chromosome changes in mantle cell lymphoma: Cytogenetic and fluorescence in situ hybridization studies 234
Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party 234
Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype 232
Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in SplenicMarginal Zone Lymphoma 230
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 230
Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival 229
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB 227
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia 227
Alterazioni cromosomiche in cellule staminali emopoietiche indotte da esposizioni ambientali o professionali. 226
Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations (J Hematol Oncol. (2016) 9 (88) DOI:10.1186/s13045-016-0320-z) 225
A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line 225
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: Correlations with clinicobiologic parameters 225
APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS 223
Angiogenesis in multiple myeloma: Correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features 223
Identifying High-Risk Chronic Lymphocytic Leukemia: A Reappraisal of the Impact of Prognostic and Predictive Factors 223
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 221
THE EUTOS LONG-TERM SURVIVAL SCORE IS PREDICTIVE FOR RESPONSE AND OUTCOME IN CML PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 220
Detection of inherited chromosomally integrated HHV-6 (ciHHV-6) in a marker chromosome 219
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 217
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 216
Molecular cytogenetic characterization of marginal zone B-cell lymphoma: correlation with clinicopathologic findings in 14 cases 212
Four novel non-random chromosome rearrangements in B-cell chronic lymphocytic leukaemia: 6p24-25 and 12p12-13 translocations, 4q21 anomalies and monosomy 21 210
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia 208
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) 205
LATE APPEARANCE of 14q32/IGH TRANSLOCATION In CHRONIC LYMPHOCYTIC LEUKEMIA. 205
“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia” 204
Abnormalities of chromosomes 1p34-36, 4p16, 4q35, 9q11-32 and +7 represent novel recurrent cytogenetic rearrangements in chronic lymphocytic leukemia 203
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 203
Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biological significance 200
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 198
In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome 198
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS 197
Cytogenetic and molecular cytogenetic characterization of 6 new cases of idiopathic hypereosinophilic syndrome 196
CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 195
Hepatosplenic T-cell lymphoma (HSTCL). 194
Clonal evolution in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 194
Multilineage involvement in the 5q- syndrome: A fluorescent in situ hybridization study on bone marrow smears 192
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 192
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated with Ibrutinib 192
Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis 191
Differences among young adults, adults and elderly chronic myeloid leukemia patients 188
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia 185
Neoplastic circulating endothelial cells in hematologic malignancies 183
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study 183
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 181
Intestinal T-cell lymphoma 180
Clinicobiological features in chronic lymphocytic leukemia with 14q32/IgH translocations. 178
Essential Thrombocythemia (ET) 175
EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIB 174
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 174
Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia 174
Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays 173
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 172
VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY? 172
Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. 166
First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era 165
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia 164
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 162
Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia 161
A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results 160
Molecular cytogenetic lesions in chronic lymphocytic leukemia 159
TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA 159
PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements 158
IN CHRONIC LYMPHOCYTIC LEUKEMIA THE AMOUNT OF PROLIFERATION CENTERS IN TISSUE-BIOPSIES CORRELATES WITH UNFAVORABLE CYTOGENETIC ABNORMALITIES 158
Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13) PDGFRB-NDE1 fusion 155
Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. 155
LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FRONTLINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY 154
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 153
Imatinib In Very Elderly CML Patients: What Can We Achieve? 152
Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough? 151
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia (letter) 150
Polycythemia vera (PV) 149
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. 149
Capitolo 1. Fisiopatologia del sangue e degli organi ematopoietici. 149
The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation 149
Totale 20.866
Salva come PNG Salva come JPEG
Categoria #
all - tutte 134.843
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 7.112
Totale 141.955
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.518 0 188 54 59 84 112 93 97 44 137 163 487
2022/20231.571 179 88 63 180 259 207 74 166 210 7 89 49
2023/2024776 79 91 37 18 38 141 41 54 24 16 26 211
2024/20253.701 94 101 271 101 486 360 68 149 646 404 507 514
2025/202612.091 986 565 902 1.462 1.617 779 1.287 694 1.161 1.284 826 528
2026/2027844 449 395 0 0 0 0 0 0 0 0 0 0
Totale 29.733